Insights Regarding the Role of Inflammasomes in Leukemia: What Do We Know?
Table 2
Potential therapeutic targets directed to the inflammasome.
Therapeutic potential
Description
Target
Phase
Ref./NTC number
IL1RAP receptor inhibition
Despite progress, there is still a need to provide additional strategies for patients with refractory AML. This study aims to evaluate the effects of immunotherapy for refractory AML cells expressing IL1RAP using chimeric antigen receptor T cells
IL1RAP
Phase I
NCT04169022
IL-1Rα receptor inhibition
This study aims to evaluate the effects of subcutaneous administration of an IL-1β receptor antagonist on the clinical status of patients with aneurysmal subarachnoid hemorrhage
IL-1Rα
Phase III
NCT03249207
BTK inhibitor
Anti-CD19 chimeric antigen receptor (CAR) T-cell has shown dramatic efficacy in B-cell malignancies, and Bruton tyrosine kinase (BTK) inhibitor agents have been validated as an effective drug to treat B-cell malignancies. Thus, combined therapies in patients with CLL after ibrutinib failure are considered feasible and safe
CD19+ cells
Phase III
NCT05020392
huCART19-IL18
Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) target CD19 cells in NHL and CLL and produce IL-18. This approach can be used by both new and relapsed patients
